Lilly’s Omvoh benefit continues for four years in UC
Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown continued benefit after four years in a Phase III open-label extension trial in patients…
Latest News
-
-
FDA lifts clinical hold on Neurizon’s ALS drug
The US Food and Drug Administration (FDA) has released its clinical hold on Neurizon Therapeutics’ NUZ‑001, paving the way for…
-
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug…
-
Pfizer shakes hands with White House on drug discounts under MFN programme
Pfizer is the first in what could be a string of pharmaceutical companies to come to an agreement with the…
-
UniQure stock surges 247% after mid-stage Huntington’s win
A Huntington’s gene therapy by UniQure has made waves after slowing disease progression by 75% in a mid-stage trial. During…
-
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary…
-
Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage
Eli Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic lymphocytic leukaemia…
-
Multiply Labs’ biomanufacturing robot to “slash cell therapy costs”
Multiply Labs has developed a robotic biomanufacturing cluster that the company claims can reduce the cost of cell and gene…
-
Bavarian Nordic’s Vimkunya makes UK debut amid Ixchiq suspension
Bavarian Nordic has launched its chikungunya vaccine, Vimkunya, in the UK. This follows the sharp rise in travel-related disease incidences…
-
ESC 2025: Novo Nordisk’s Wegovy superior to Zepbound in reducing CV events
Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA) Wegovy (semaglutide) showed a significant reduction in cardiovascular (CV) events compared to Eli…
